The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced.

The US Food and Drug Administration (FDA) has approved tezepelumab-ekko (Tezspire) as a first in class treatment for severe asthma in adults and pediatric patients aged 12 years and older. It is not ...

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

Cold air can irritate the airways that carry air into the lungs, potentially causing symptoms like coughing, chest tightness, and trouble breathing.

In assessing and managing patients presenting with acute, life-threatening asthma, if the exacerbation does not resolve relatively quickly, clinicians need to start looking for other causes of the ...

An asthma attack is a sudden worsening of asthma symptoms caused by inflammation and a narrowing of the airways. This can make breathing difficult and, in severe cases, be life-threatening. Asthma ...

RESEARCH TRIANGLE PARK, N.C., Dec. 2, 2015 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Nucala® (mepolizumab), the first and only biologic add-on therapy for people 12 ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Amgen today announced TEZSPIRE™ (tezepelumab-ekko) is now available for shipment to wholesalers in the US. TEZSPIRE was approved by the US Food and ...

I've known I wanted to be a doctor since a young age, and felt compelled to specialize in allergy very early on. As a patient-turned-physician, I know firsthand the impact allergy and asthma ...

On Saturday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AMGN) announced full results from the Phase 3, registrational WAYPOINT trial evaluating the efficacy and safety of tezepelumab in ...